A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the use in patients with type 2 diabetes to lower blood sugar levels.
Rybelsus is the first drug in its class, called glucagon-like peptides (GLP-1), and is now approved for use in the United States. Before its approval the drug could only be injected.
